


Patent Claims

1. Compounds of the formula I



in which

- D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,
- X denotes -C=O or C(R³)₂,
- W denotes -[C(R³)₂]_n-,
- R¹ denotes H or A, which may be substituted by OR³, S(O)_nR³, N(R³)₂, CN, COOR³, CON(R³)₂, OCON(R³)₂, N(R³)COOR³, N(R³)CON(R³)₂, N(R³)SO₂R³, SO₂N(R³)₂ or -C≡C-,
- R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R³ denotes H or A,
- Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, =NR², =N-CN, =N-NO₂, =NOR², =NCOR², =NCOOR², =NOCOR² and may furthermore be mono-, di- or trisubstituted by R², Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_nA,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S

atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

5 Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂N(R²)₂, S(O)_nA, -[C(R³)₂]_n-COOR² or -O-[C(R³)₂]_o-COOR²,

10 Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_o-COOR³,

15 Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, =N(R²)₂, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR², -[C(R³)₂]_n-N(R³)₂, NO₂, CN, -[C(R³)₂]_n-COOR², -[C(R³)₂]_n-CON(R²)₂, -[C(R³)₂]_n-NR²COA, NR²CON(R²)₂, -[C(R³)₂]_n-NR²SO₂A, COR², SO₂NR² and/or S(O)_nA,

25 Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR³ and/or S(O)_nA,

30 Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2,

35 o denotes 1, 2 or 3,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1,
in which
5 D denotes an aromatic five-ring heterocycle having 1 to 2 N, O
and/or S atoms which is unsubstituted or mono- or disubsti-
tuted by Hal,
and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
10
3. Compounds according to Claim 1 or 2,
in which
D denotes a thienyl ring which is mono- or disubstituted by Hal,
15 and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
4. Compounds according to one or more of Claims 1-3 ,
in which
20 R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
- 25 5. Compounds according to one or more of Claims 1-4,
in which
 R^1 denotes H or A, which may be substituted by OR^3 , $CON(R^3)_2$,
 $N(R^3)_2$, $S(O)_nR^3$, $COOR^3$, $OCON(R^3)_2$, $N(R^3)COOR^3$ or $-C\equiv C-$,
30 and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
6. Compounds according to one or more of Claims 1-5,
in which
35 X denotes $-C=O$,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

- 5 7. Compounds according to one or more of Claims 1-6,
 in which
 W is absent,
 and pharmaceutically usable derivatives, solvates and stereoisomers
 thereof, including mixtures thereof in all ratios.
- 10 8. Compounds according to one or more of Claims 1-7,
 in which
 Y denotes Ar-diyl,
 and pharmaceutically usable derivatives, solvates and stereoisomers
15 thereof, including mixtures thereof in all ratios.
9. Compounds according to one or more of Claims 1-8,
 in which
20 T denotes a mono- or bicyclic saturated, unsaturated or aro-
 matic heterocycle having 1 to 2 N and/or O atoms which is
 mono- or disubstituted by =O, =S, =NR², =N-CN, =N-NO₂,
 =NR², =NCOR², =NCOOR² or =NOCOR² and may further-
25 more be mono- or disubstituted by Hal or A,
 and pharmaceutically usable derivatives, solvates and stereoisomers
 thereof, including mixtures thereof in all ratios.
- 30 10. Compounds according to one or more of Claims 1-9,
 in which
 T denotes a mono- or bicyclic saturated or unsaturated hetero-
 cycle having 1 to 2 N and/or O atoms which is mono- or di-
 substituted by =O, =S or =NH,
35 and pharmaceutically usable derivatives, solvates and stereoisomers
 thereof, including mixtures thereof in all ratios.

11. Compounds according to one or more of Claims 1-10,
in which
- 5 T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,
and pharmaceutically usable derivatives, solvates and stereoisomers
10 thereof, including mixtures thereof in all ratios.
12. Compounds according to one or more of Claims 1-11,
in which
- 15 Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂ or CN,
and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
- 20 13. Compounds according to one or more of Claims 1-12,
in which
- Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,
25 and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
14. Compounds according to one or more of Claims 1-13,
in which
- 30 D denotes aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,
- 35 R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂, S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
X denotes -C=O or CH₂,
W is absent,
Y denotes Ar-diyl,
5 Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,
T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono-
10 or disubstituted by =O, =S or =NH,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

15 15. Compounds according to one or more of Claims 1-14,
in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

20 R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂, S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH₂,

W is absent,

25 Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,

30 T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

35

16. Compounds according to one or more of Claims 1-15,
in which

D denotes thienyl or phenyl, each of which is mono- or
disubstituted by Hal,
5 R¹ denotes H or A, which may be substituted by OR³,
CON(R³)₂, N(R³)₂, S(O)_nR³, COOR³, OCON(R³)₂,
N(R³)COOR³ or -C≡C-,
R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
10 R³ denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
X denotes -C=O or CH₂,
W is absent or denotes CH₂,
Y denotes Ar-diyl,
15 A denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one
or two CH₂ groups may be replaced by O or S atoms and/or
by -CH=CH- groups and/or also 1-7 H atoms may be
replaced by F,
20 Ar denotes phenyl which is unsubstituted or mono- or disubsti-
tuted by A and/or Hal,
T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-
4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl,
pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl,
25 each of which is mono- or disubstituted by =O or =NH,
and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.

- 30 17. Compounds according to Claim 1, selected from the group

(S)-2-([(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomor-
pholin-4-yl)phenyl]-4-methylvaleramide,

35 (S)-2-([(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-
(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

5

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyrazin-1-yl)phenyl]-4-methylvaleramide,

10

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

15

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]acetamide,

20

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

25

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]butyramide,

30

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonylpropionamide,

(R)-2-[(4-chlorophenylcarbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

35

(R)-2-[(4-chlorophenylcarbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(N,N-dimethylamino)propionamide,

(R)-2-[(5-bromothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-methyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfanylpropionamide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-methylbutyramide,

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]propionamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-2-butylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,

5

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfanylpropionamide,

10

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

15

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

20

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

25

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

30

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

35

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

5

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

10

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

15

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxopiperidin-1-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

20

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

25

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

30

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonylamino)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonylamino)propionamide,

35

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-methyladipamide,

(S)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-methyladipamide,

5

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

10

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

15

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

20

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethoxy-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

25

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

30

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-allylpropionamide,

35

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-propoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(2-methoxyethoxy)propionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethoxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(2-methoxyethoxy)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophen-2-ylmethyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,


(2R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

18. Process for the preparation of compounds of the formula I according to Claims 1-17 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that


a) a compound of the formula II



in which

W, Y and T have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and


R¹, m, X and D have the meanings indicated in Claim 1,

or

b) for the preparation of compounds of the formula I,

in which X denotes -C=O,

a compound of the formula IV



in which R¹, m, W, Y and T have the meanings indicated in Claim 1,

is reacted with a compound of the formula V

D-CO-L V

in which


L denotes Cl, Br, I or a free or reactively functionally modified
OH group, and

D has the meaning indicated in Claim 1,

or

c) for the preparation of compounds of the formula I
in which X denotes CH₂,

a compound of the formula IV



in which R¹, m, W, Y and T have the meanings indicated in Claim 1,

is reacted with a compound of the formula VI

D-CHO VI

in which

D has the meaning indicated in Claim 1,
in a reductive amination,

and/or

a base or acid of the formula I is converted into one of its salts.

19. Compounds of the formula I according to one or more of Claims 1 to 17 as inhibitors of coagulation factor Xa.

20. Compounds of the formula I according to one or more of Claims 1 to 17 as inhibitors of coagulation factor VIIa.
- 5 21. Medicaments comprising at least one compound of the formula I according to one or more of Claims 1 to 17 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
- 10 22. Medicaments comprising at least one compound of the formula I according to one or more of Claims 1 to 17 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
- 15 23. Use of compounds according to one or more of Claims 1 to 17 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
- 20 24. Set (kit) consisting of separate packs of
- 25 (a) an effective amount of a compound of the formula I according to one or more of Claims 1 to 17 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
- 30 and
- 35 (b) an effective amount of a further medicament active ingredient.